<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01041482</url>
  </required_header>
  <id_info>
    <org_study_id>Bay 43-9006</org_study_id>
    <nct_id>NCT01041482</nct_id>
  </id_info>
  <brief_title>A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Advanced Renal-Cell Carcinoma</brief_title>
  <acronym>AGuo</acronym>
  <official_title>A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Locally Advanced Renal-Cell Carcinoma After Radical Nephrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing University of Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Province Centers for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A one-arm,open,multi-center study, to evaluate sorafenib (400mg twice daily ) as a adjuvant&#xD;
      to prevent recurrence of RCC(renal cell carcinoma) patients after radical nephrectomy with a&#xD;
      high-risk of recurring. To observe disease-free survival and the survival rate in 3 years,5&#xD;
      years.&#xD;
&#xD;
      The purpose of this study is:&#xD;
&#xD;
        -  To study the efficacy of Sorafenib as an adjuvant therapy for reducing recurrence rate&#xD;
           in locally advanced renal-cell carcinoma (RCC) after radical nephrectomy.&#xD;
&#xD;
        -  To observe the incidence of hand-foot skin reaction (HFSR) after the Urea (10% or 5%)&#xD;
           based cream intervention treatment.&#xD;
&#xD;
      The primary end point is the disease-free survival(DFS).The secondary end point is overall&#xD;
      survival(OS),the drug safety and tolerance, the occurrence of hand foot skin reaction(HFSR)&#xD;
      at the week of 3,6,12,the skin toxicity(not include HFSR) higher than CTCAE(Common&#xD;
      Terminology Criteria for Adverse Events) Grade 2 at the 12th week, the incidence of HFSR&#xD;
      after the Urea (10% or 5%) based cream intervention treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A one-arm, open, multi-center study, to evaluate sorafenib (400mg twice daily) as a adjuvant&#xD;
      to prevent recurrence of RCC(renal cell carcinoma) patients after radical nephrectomy with a&#xD;
      high-risk of recurring. To observe disease-free survival and the survival rate in 3 years,&#xD;
      and 5 years. To observe the incidence of hand-foot skin reaction (HFSR) after the Urea (10%&#xD;
      or 5%) based cream intervention treatment. 140 subjects are prospected to enter the trial.&#xD;
&#xD;
      The sorafenib adjuvant therapy is unremitting with a time of 12 months. For a convenient&#xD;
      record, every 6 weeks is regarded as a single observational cycle. The end-point are&#xD;
      recurrence, not being tolerant to the toxicity, need to stop the intervening study or&#xD;
      withdrawing the informed consent. It is necessary to evaluate the efficacy and safety every 6&#xD;
      weeks. At the screening stage and every 12 weeks imaging review are performed such as&#xD;
      abdominal and chest CT or MRI, the imaging methods of a single subject should be in&#xD;
      uniformity during the trial.&#xD;
&#xD;
      The post-treatment evaluation are performed 30 days after the last usage of the adjuvant in&#xD;
      order to collect all the adverse events (AE) and the survival rates of all the subjects. The&#xD;
      agent-relevant AE (known or unknown) should be reported to the drug safety institution, the&#xD;
      patients should be visited until the events solved, except the events can not be solved for&#xD;
      the subjects' underlying diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival</measure>
    <time_frame>November 2008-November 2013</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>November 2008-November 2013</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To study the efficacy of Sorafenib as an adjuvant therapy for reducing recurrence rate in locally advanced renal-cell carcinoma (RCC) after radical nephrectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib</intervention_name>
    <description>sorafenib 400mg twice daily</description>
    <arm_group_label>sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Preoperative Criteria&#xD;
&#xD;
          -  Renal local advanced renal cell carcinoma and be suitable to radical nephrectomy.&#xD;
&#xD;
          -  Tumor &gt;=7cm, the lymph nodes in metastasis can be resectable, the renal vein or&#xD;
             inferior caval vein with metastatic thrombus can be resectable also, clinical&#xD;
             staging&gt;=T2anyNMo.&#xD;
&#xD;
          -  Resectable tumor with multiple-lesion in ipsolateral kidney Enrolment Criteria&#xD;
&#xD;
          -  No distant metastasis.&#xD;
&#xD;
          -  Not undergoing any adjuvant or systematic anti-tumor therapy, such as chemotherapy,&#xD;
             biotherapy or radiotherapy.&#xD;
&#xD;
          -  After the nephrectomy 4-12 weeks and should be recovery in the postoperative&#xD;
             complications.&#xD;
&#xD;
          -  ECOG scores 0-1.&#xD;
&#xD;
          -  Referring to the Scoring Algorithm to Predict Metastasis after Radical Nephrectomy in&#xD;
             Patients with clear cell renal cell carcinoma, all the patients score higher than 6.&#xD;
             Metastatic lymph node with clinical diagnosis have been resected, all the resected&#xD;
             specimen edge be negative in pathological detection.&#xD;
&#xD;
        The pathological diagnosis of renal cell carcinoma:&#xD;
&#xD;
          -  No remnant tumor with postoperative imaging screening with CT or MRI.&#xD;
&#xD;
          -  The liver and renal function, hemocytogenesis function meet the below criteria within&#xD;
             the 4 weeks before the enrollment.&#xD;
&#xD;
               -  Granulocytes count &gt;1500/mm3&#xD;
&#xD;
               -  Blood platelet &gt;100000/mm3&#xD;
&#xD;
               -  Creatinine&lt;2 times of the upper of the reference value&#xD;
&#xD;
               -  Total bilirubin&lt;1.5 times of the upper of the reference value&#xD;
&#xD;
               -  Alanine aminotransferase/aspartate aminotransferase&lt;2.5 times of the upper of the&#xD;
                  reference value&#xD;
&#xD;
               -  The informed consent has been endorsed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other coincident carcinoma, but not including carcinoma in situ of cervix and basal&#xD;
             cell epithelioma after radical therapy and bladder carcinoma superficially(Ta,Tis,T1)&#xD;
             or carcinoma having been cured 3 years ago.&#xD;
&#xD;
          -  Cardiac dysrhythmia need agent intervention(not including β-receptor inhibitive or&#xD;
             digoxin treatment), coronary heart disease, myocardial infarction occurred in the&#xD;
             later 6 months, heart failure assessment higher than NYHA II&#xD;
&#xD;
          -  Seriously active infection with bacteria or fungus&#xD;
&#xD;
          -  HIV infection or HBV/HCV infection with IFN-a intervention.&#xD;
&#xD;
          -  Dysfunction in blood coagulation.&#xD;
&#xD;
          -  Epilepsia with drug treatment.&#xD;
&#xD;
          -  Those cannot take tablets orally.&#xD;
&#xD;
          -  Allogeneic organ transplantation.&#xD;
&#xD;
          -  Drug abuse or concomitant conditions such as psychologically or socially factors which&#xD;
             may intervene the assessment.&#xD;
&#xD;
          -  Hypersensitiveness to the studying adjuvant or the trial-relevant drugs.&#xD;
&#xD;
          -  Pregnancy or lactation, pregnancy test must be negative within the 14 days before the&#xD;
             trial beginning, either females or males must be contraceptive during the trial.&#xD;
&#xD;
          -  The following concomitant therapeutics must be excluded:&#xD;
&#xD;
               -  Anti-tumor agents, immunological or hormonal therapy&#xD;
&#xD;
               -  Radiotherapy&#xD;
&#xD;
               -  Biological therapeutics such as G-CSF or GM-CSF&#xD;
&#xD;
               -  Autologous bone marrow transplantation or stem cell treatment&#xD;
&#xD;
               -  The other trial medicine therapeutics&#xD;
&#xD;
               -  Bevacizumab treatment or other agents effected in VEGF or VEGF-receptor, such as&#xD;
                  inhibitive in Raf or MEK&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>China Academy of Medical Sciences Jianhui Ma China Academy of Medical Sciences, Doctor</last_name>
    <phone>01086108778</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>China Academy of Medical Sciences Jianhui Ma China Academy of Medical Sciences</last_name>
    <phone>01086108778</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jianhui Ma</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhui Ma Jianhui Ma Jianhui Ma, Doctor</last_name>
      <phone>01086108878</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>December 30, 2009</study_first_submitted>
  <study_first_submitted_qc>December 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2009</study_first_posted>
  <last_update_submitted>January 5, 2010</last_update_submitted>
  <last_update_submitted_qc>January 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chinese Academy of Medical Sciences</name_title>
    <organization>Chinese Academy of Medical Sciences</organization>
  </responsible_party>
  <keyword>sorafenib</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>disease free survival</keyword>
  <keyword>Hand food skin reaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

